Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ESPR
- Price
- 1.07
- Stock movement down
- -0.03 (-2.73%)
- Company name
- Esperion Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 215.74M
- Ent value
- 755.34M
- Price/Sales
- 0.73
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -23.09%
- 1 year return
- -62.72%
- 3 year return
- -40.96%
- 5 year return
- -52.44%
- 10 year return
- -34.56%
Last updated: 2025-08-27
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ESPR does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.73 |
| Price to Book | - |
| EV to Sales | 2.56 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 201.62M |
| EPS (TTM) | -0.45 |
| FCF per share (TTM) | -0.13 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 295.45M |
| Gross profit (TTM) | 241.01M |
| Operating income (TTM) | 16.45M |
| Net income (TTM) | -86.77M |
| EPS (TTM) | -0.45 |
| EPS (1y forward) | -0.04 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 81.57% |
| Operating margin (TTM) | 5.57% |
| Profit margin (TTM) | -29.37% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 144.72M |
| Net receivables | 67.82M |
| Total current assets | 307.56M |
| Goodwill | 0.00 |
| Intangible assets | 56.00K |
| Property, plant and equipment | 6.50M |
| Total assets | 314.11M |
| Accounts payable | 34.86M |
| Short/Current long term debt | 268.96M |
| Total current liabilities | 165.87M |
| Total liabilities | 684.32M |
| Shareholder's equity | -370.21M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -25.76M |
| Capital expenditures (TTM) | 317.00K |
| Free cash flow (TTM) | -26.07M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -27.62% |
| Return on Invested Capital | 83.00% |
| Cash Return on Invested Capital | 24.94% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.10 |
| Daily high | 1.12 |
| Daily low | 1.05 |
| Daily Volume | 5.15M |
| All-time high | 115.30 |
| 1y analyst estimate | 5.80 |
| Beta | 0.82 |
| EPS (TTM) | -0.45 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 5 Nov 2025 |
Downside potential
Loading...
Downside potential data
| ESPR | S&P500 | |
| Current price drop from All-time high | -99.07% | -3.04% |
| Highest price drop | -99.37% | -56.47% |
| Date of highest drop | 14 May 2025 | 9 Mar 2009 |
| Avg drop from high | -67.76% | -11.04% |
| Avg time to new high | 51 days | 12 days |
| Max time to new high | 2538 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
215.74M
Marketcap category
Small-cap
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Employees
304
Website
Investor relations
-
SEC filings
CEO
Tim M. Mayleben
Country
USA
City
Ann Arbor
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page